2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphomas, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

1244 Efficacy of CAR T-cell and bispecific T-cell engager therapies for immune thrombocytopenia (ITP) secondary to hematologic malignancy

Saarang Deshpande, MD, Debbie Jiang, M.D.2, Rebecca K. Leaf, MD3, Andrew B. Song, MD4, Hanny Al-Samkari, MD5
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
2 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
3 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
4 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
5 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States

Background Immune thrombocytopenia (ITP) secondary to B-cell and plasma-cell malignancies is associated with substantial morbidity and may complicate anti-neoplastic therapy. Immune effector cell (IEC) therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BiTE) therapies, have proven efficacy for these malignancies and have also demonstrated efficacy in autoimmune cytopenias, primarily in case reports. However, evidence supporting their use in ITP secondary to malignancy remains limited.

Methods We performed a multicenter observational study of patients (pts) with ITP secondary to hematologic malignancy who received IEC therapy for treatment of the malignancy. Pts were included regardless of ITP duration or prior ITP-directed therapy if they were not in a complete response (CR) at the time of IEC therapy. ITP was distinguished from other etiologies of thrombocytopenia based on treating clinician documentation, followed by a separate hematologist’s assessment of characteristic response to first-line ITP therapy, bone marrow biopsy findings, and clinical history. The primary endpoint was platelet response according to the IWG definition: a platelet count ≥30 × 10⁹/L and at least twice the baseline count on two or more measurements at least 7 days apart, without clinically significant bleeding. The key secondary endpoint was CR, defined similarly but requiring a platelet count ≥100 × 109/L. Additional secondary endpoints included time to response and response duration.

Results A total of 22 pts met inclusion criteria out of 539 pts identified via database query for IEC therapies and ITP (inclusion rate 4.1%). Median age was 67 years (IQR 60-78), and 50% were female. Underlying malignancies included lymphoma (n=17, 77%; predominantly DLBCL, n=11) and multiple myeloma (n=5, 23%). The cohort comprised 13 CAR-T (59%) and 9 BiTE (41%) recipients with antigenic targets of CD19 (55%), CD20 (23%), BCMA (18%), and GPRC5D (5%). ITP was newly diagnosed in 8 pts, persistent in 3, and chronic in 11 according to IWG definitions. Before IEC therapy, pts had received a median of 2 prior ITP treatments (IQR 2–3), including corticosteroids (86%), IVIG (64%), and TPO-RAs (59%). As part of anti-neoplastic therapy, 77% had also received anti-CD20 antibodies and 45% had received BTK inhibitors. Ten pts (45%) received concomitant ITP-directed treatment at the time of IEC therapy. Median platelet counts at ITP diagnosis, nadir, and pre-IEC were 26 (IQR 9-48), 9 (IQR 1-23), and 37 (IQR 21-64) ×109/L, respectively. Median follow-up was 12.6 months (IQR 5.3-22.6) with 12 pts dying. CRS occurred in 19 (86%; all grade 1/2), and ICANS occurred in 7 (32%; 57% grade 1/2) pts.

Platelet response after IEC therapy was achieved in 21 of 22 pts for a response rate of 95.5% (95% CI 78.2-99.2%). CR was achieved in 19 pts (86.4%; 95% CI 66.7-95.3%). Among responders, median time to response was 15 days (IQR 11-33; range 6-69). Among pts with ITP secondary to lymphoma, the median time to response was shorter with CD19-targeted CAR-T than with CD20-targeted BiTE therapy (13 vs 31 days; P = .078). Malignancy type or ITP phase did not predict for time to ITP response. Median platelet counts at days 30 and 90 after IEC therapy were 69 (IQR 40-137) and 103 (IQR 84-143). Nine out of ten pts (90%) on concomitant ITP-directed treatment at the time of IEC therapy discontinued that treatment.

Estimated ITP relapse-free probability was 89.1% at both 6 and 12 months and 70.9% at 24 months. Notably, malignancy relapse occurred earlier (median 530 days) and more frequently (10 vs 6 events) than ITP relapse. In 9 pts, there was progression or relapse of malignancy without recurrence of ITP. No pts had ITP relapse in the absence of malignancy progression or relapse.

Conclusions In this multicenter observational cohort of patients with lymphoma and multiple myeloma, to our knowledge the first and largest of its kind to date, CAR-T and BiTE therapies resulted in a high rate of secondary ITP response with predominantly durable complete responses achieved approximately two weeks after IEC therapy. Response of ITP to IEC therapy frequently persisted despite malignancy progression, suggesting that the durability of ITP remission is at least partly independent of ongoing malignancy control. These data demonstrate the efficacy of IEC therapies for ITP secondary to hematologic malignancies and support their continued development for primary ITP.

Saarang Deshpande, MD: No relevant conflicts of interest to declare.